ATE384520T1 - Kombinierte verwendung von einem fibrat und von orlistat zur behandlung von obesitas - Google Patents
Kombinierte verwendung von einem fibrat und von orlistat zur behandlung von obesitasInfo
- Publication number
- ATE384520T1 ATE384520T1 AT04720007T AT04720007T ATE384520T1 AT E384520 T1 ATE384520 T1 AT E384520T1 AT 04720007 T AT04720007 T AT 04720007T AT 04720007 T AT04720007 T AT 04720007T AT E384520 T1 ATE384520 T1 AT E384520T1
- Authority
- AT
- Austria
- Prior art keywords
- fibrate
- orlistat
- obesitas
- treatment
- combined use
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/223—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of alpha-aminoacids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Child & Adolescent Psychology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Dental Preparations (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP03290625A EP1457206A1 (de) | 2003-03-13 | 2003-03-13 | Kombinierte Verwendung von einem Fibrat und von Orlistat zur Behandlung von Obesitas |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE384520T1 true ATE384520T1 (de) | 2008-02-15 |
Family
ID=32749013
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT04720007T ATE384520T1 (de) | 2003-03-13 | 2004-03-12 | Kombinierte verwendung von einem fibrat und von orlistat zur behandlung von obesitas |
Country Status (19)
Country | Link |
---|---|
US (1) | US20070078179A1 (de) |
EP (2) | EP1457206A1 (de) |
JP (1) | JP4928256B2 (de) |
CN (1) | CN100562313C (de) |
AT (1) | ATE384520T1 (de) |
AU (1) | AU2004218938B2 (de) |
BR (1) | BRPI0408322A (de) |
CA (1) | CA2518205C (de) |
DE (1) | DE602004011486T2 (de) |
DK (1) | DK1601352T3 (de) |
EA (1) | EA009127B1 (de) |
ES (1) | ES2300750T3 (de) |
HK (1) | HK1083767A1 (de) |
IL (1) | IL170519A (de) |
MX (1) | MXPA05009718A (de) |
NO (1) | NO20054700L (de) |
PT (1) | PT1601352E (de) |
WO (1) | WO2004080450A2 (de) |
ZA (1) | ZA200507227B (de) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2617688C (en) * | 2007-02-22 | 2015-08-18 | Alpex Pharma S.A. | Solid dosage formulations containing weight-loss drugs |
EP2625968A1 (de) * | 2007-09-12 | 2013-08-14 | Københavns Universitet | Zusammensetzungen und methoden zur verstärkung der hungerunterdrückung und zum reduzieren der verdaulichkeit der nichtfettenergiesättigung |
US20120053172A1 (en) | 2009-02-12 | 2012-03-01 | Cooperatieve Mirzorg U.A. | Use of a combination of diazoxide and metformin for treating obesity or obesity related disorders |
WO2011130302A2 (en) | 2010-04-12 | 2011-10-20 | Reata Pharmaceuticals, Inc. | Method of treating obesity using antioxidant inflammation modulators |
MX336980B (es) * | 2010-12-21 | 2016-02-09 | Senosiain S A De C V Lab | Combinacion y composicion para el tratamiento de obesidad. |
CA2895827A1 (en) * | 2012-12-21 | 2014-06-26 | Merck Patent Gmbh | Magnesium hydroxide carbonate as excipient in pharmaceutical preparations having improved release of active ingredient |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1247547A (en) * | 1983-06-22 | 1988-12-28 | Paul Hadvary | Leucine derivatives |
CA1328881C (en) * | 1984-12-21 | 1994-04-26 | Pierre Barbier | Process for the manufacture of oxetanones |
TW438784B (en) * | 1997-08-29 | 2001-06-07 | Ssp Co Ltd | Triazole derivative or salt thereof and pharmaceutical composition for treating mycosis containing the same |
PH12000002657B1 (en) * | 1999-10-12 | 2006-02-21 | Bristol Myers Squibb Co | C-aryl glucoside SGLT2 inhibitors |
US6515117B2 (en) * | 1999-10-12 | 2003-02-04 | Bristol-Myers Squibb Company | C-aryl glucoside SGLT2 inhibitors and method |
CA2324801A1 (en) * | 1999-11-10 | 2001-05-10 | Andrew Gordon Swick | Use of apo b secretion/mtp inhibitors and anti-obesity agents |
WO2001060807A1 (en) * | 2000-02-18 | 2001-08-23 | Merck & Co. Inc. | Aryloxyacetic acids for diabetes and lipid disorders |
EP1424070A1 (de) * | 2002-11-28 | 2004-06-02 | Fournier Laboratories Ireland Limited | Zusammensetzung von einem PPAR-alpha Agonisten und Metformin zur Senkung des Serumtriglyceridspiegels |
-
2003
- 2003-03-13 EP EP03290625A patent/EP1457206A1/de not_active Withdrawn
-
2004
- 2004-03-12 DE DE602004011486T patent/DE602004011486T2/de not_active Expired - Lifetime
- 2004-03-12 ES ES04720007T patent/ES2300750T3/es not_active Expired - Lifetime
- 2004-03-12 MX MXPA05009718A patent/MXPA05009718A/es active IP Right Grant
- 2004-03-12 DK DK04720007T patent/DK1601352T3/da active
- 2004-03-12 CA CA2518205A patent/CA2518205C/en not_active Expired - Fee Related
- 2004-03-12 AT AT04720007T patent/ATE384520T1/de active
- 2004-03-12 ZA ZA200507227A patent/ZA200507227B/xx unknown
- 2004-03-12 AU AU2004218938A patent/AU2004218938B2/en not_active Ceased
- 2004-03-12 US US10/548,909 patent/US20070078179A1/en not_active Abandoned
- 2004-03-12 EA EA200501259A patent/EA009127B1/ru not_active IP Right Cessation
- 2004-03-12 JP JP2006505148A patent/JP4928256B2/ja not_active Expired - Fee Related
- 2004-03-12 PT PT04720007T patent/PT1601352E/pt unknown
- 2004-03-12 WO PCT/EP2004/004010 patent/WO2004080450A2/en active IP Right Grant
- 2004-03-12 EP EP04720007A patent/EP1601352B1/de not_active Expired - Lifetime
- 2004-03-12 BR BRPI0408322-9A patent/BRPI0408322A/pt not_active IP Right Cessation
- 2004-03-12 CN CNB2004800068916A patent/CN100562313C/zh not_active Expired - Fee Related
-
2005
- 2005-08-25 IL IL170519A patent/IL170519A/en not_active IP Right Cessation
- 2005-10-12 NO NO20054700A patent/NO20054700L/no not_active Application Discontinuation
-
2006
- 2006-05-29 HK HK06106181A patent/HK1083767A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
US20070078179A1 (en) | 2007-04-05 |
EA009127B1 (ru) | 2007-10-26 |
CN100562313C (zh) | 2009-11-25 |
IL170519A0 (en) | 2006-10-05 |
NO20054700L (no) | 2005-10-12 |
AU2004218938B2 (en) | 2009-04-09 |
CA2518205A1 (en) | 2004-09-23 |
BRPI0408322A (pt) | 2006-03-14 |
WO2004080450A2 (en) | 2004-09-23 |
CA2518205C (en) | 2012-05-08 |
CN1826108A (zh) | 2006-08-30 |
PT1601352E (pt) | 2008-04-07 |
MXPA05009718A (es) | 2005-10-18 |
DK1601352T3 (da) | 2008-05-13 |
ES2300750T3 (es) | 2008-06-16 |
WO2004080450A3 (en) | 2005-02-24 |
EP1601352A2 (de) | 2005-12-07 |
HK1083767A1 (en) | 2006-07-14 |
AU2004218938A1 (en) | 2004-09-23 |
IL170519A (en) | 2010-12-30 |
DE602004011486D1 (de) | 2008-03-13 |
DE602004011486T2 (de) | 2009-01-15 |
JP2006520365A (ja) | 2006-09-07 |
EP1601352B1 (de) | 2008-01-23 |
EP1457206A1 (de) | 2004-09-15 |
EA200501259A1 (ru) | 2006-02-24 |
JP4928256B2 (ja) | 2012-05-09 |
ZA200507227B (en) | 2006-11-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE414089T1 (de) | Verwendung von rapamycin und dessen derivaten zur behandlung von knochenverlust | |
DE602004020072D1 (de) | 1,2,3,4-tetrasubstituiertes indol zur behandlung von atemwegserkrankungen | |
ATE555803T1 (de) | Verwendung von osteopontin zur behandlung und/oder vorbeugung von neurologischen erkrankungen | |
DE60335293D1 (de) | Pyrrolopyridazin-verbindungen und verwendungsverfahren dafür zur behandlung von proliferativen erkrankungen | |
ATE428413T1 (de) | Neue verwendung von peptidverbindungen zur behandlung ovn zentralen neuropathischen schmerzen | |
DE502004010131D1 (de) | Pyridopyrimidinone zur behandlung von krebserkrankungen | |
DE60327074D1 (de) | Fluorobenzamide zur behandlung von alzheimer oder seniler dementia | |
ATE472329T1 (de) | Verwendung der kombination von ciclesonid und antihistaminika zur behandlung von allergischer rhinitis | |
NO20054700L (no) | Anvendelse av et fibrat og orlistat for behandling av fedme | |
DE60219687D1 (de) | Aroylpyrrolheteroeryl und methanole zur behandlung von störungen des zentralnervensystems | |
ATE361755T1 (de) | Verwendung von thrombomodulinanaloga zur regenerierung von rückenmarkverletzungen | |
ATE494903T1 (de) | Verwendung von slurp-1 zur behandlung von krankheiten, die durch störungen der acetylcholinerezeptoren ausgelöst werden | |
DE60213365D1 (de) | Verwendung von mglur5 antagonisten zur behandlung von pruritischen zuständen | |
ATE408602T1 (de) | Monohyroxycarbamezepin zur verwendung bei der herstellung eines medikaments zur behandlung von affektiver psychose, aufmerksamkeits störungen und neuropathischen schmerzen | |
DE60318081D1 (de) | Verwendung von brimonidine zur behandlung von dementia und morbus parkinson | |
ATE427754T1 (de) | Verwendung von il-17f zur behandlung und/oder pravention von neurologischen erkrankungen | |
ATE498397T1 (de) | Verwendung von isorhamnetin zur behandlung von depressiven verstimmungen und erkrankungen | |
DE60219495D1 (de) | Verwendung von Interleukin-18 zur Behandlung von UV-assoziierten Hautkrankheiten | |
DE602004026830D1 (de) | Verwendung von pvp-iod liposomen zur behandlung von atopischer dermatitis | |
ATE386748T1 (de) | Verwendung von liganden von cd52 antigen zur behandlung von soliden tumoren und von knochenkrebserkrankungen | |
DE60326348D1 (de) | Makrozyclen zur behandlung von krebserkrankungen | |
ATE401321T1 (de) | Beta-lactame zur behandlung von erkrankungen des zns | |
ATE476185T1 (de) | Verwendung von ciclesonid zur behandlung von entzündlichen darmerkrankungen | |
DE60321377D1 (de) | Verwendung von levocetirizin zur behandlung von persistierender allergischer rhinitis | |
DE10311984A8 (de) | Verwendung von NEP-assoziierten Molekülen zur Behandlung von nichtimmunogenen-nichthypertensiven Zivilisationskrankheiten |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification |
Ref document number: 1601352 Country of ref document: EP |